OSTEOSARCOMA

This study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…

This study tests two oral drugs, eflornithine (DFMO) and AMXT 1501, in children and young adults up to age 26 with certain cancers that have come back or not responded to treatment. The cancers include neuroblastoma, brain tumors, and sarcomas. The goal is to find a safe dose and…

This phase 2 trial tests a daily oral drug called zanzalintinib in 70 adults with advanced or metastatic bone sarcomas that cannot be removed by surgery. The study includes four groups based on sarcoma type. Researchers will check if the drug is safe and helps control the cancer.

This early-phase trial tests a personalized cancer vaccine (SarcVac) combined with immune-boosting drugs and, in some patients, specially grown immune cells. The goal is to see if this approach is safe and can shrink tumors in 16 adults with advanced bone or soft tissue sarcoma w…

This study tests whether adding eflornithine (DFMO) to standard chemotherapy can help teens and young adults with Ewing sarcoma or osteosarcoma live longer without their cancer coming back. About 406 participants will join one of five groups based on their cancer type and stage. …

This early-phase study tests a combination of two drugs—losartan (a blood pressure medicine) and sunitinib (a cancer drug)—in people aged 10 and older with osteosarcoma (a type of bone cancer) that has returned or not responded to treatment. The main goal is to find the safest do…

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

This early-phase trial is testing whether combining an immunotherapy drug (atezolizumab) with targeted radiation and surgery is safe for people whose osteosarcoma has come back in the lungs. About 12 participants will receive the drug, radiation to one lung nodule, and then surge…

This study tests whether freezing tumors (cryoablation) combined with an immunotherapy drug (camrelizumab) can shrink advanced soft tissue sarcomas that have stopped responding to standard treatments. About 57 participants aged 14 to 70 will receive this combination. The main goa…

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This study looks at whether a drug called dexrazoxane can help prevent heart damage in children and teens who have been treated for certain cancers like leukemia, lymphoma, and osteosarcoma. Researchers will measure heart function and blood markers in 420 survivors to see if dexr…

This early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is …

This expanded access program offers L-MTP-PE, an investigational drug that activates white blood cells to fight cancer, to people with osteosarcoma. Eligible patients include those with newly diagnosed or relapsed osteosarcoma who have had surgery to remove all detectable cancer.…

This early-phase trial is testing a new type of immunotherapy called B7-H3 CAR T cells in children and young adults whose solid tumors (such as neuroblastoma, sarcoma, or osteosarcoma) have come back or not responded to standard treatments. The therapy involves taking a patient's…

This early-stage trial is testing a new cell therapy called DIT309 for people with advanced bone or soft tissue sarcomas that have stopped responding to standard treatments. The therapy uses the patient's own immune cells, modified to better recognize and attack cancer cells. The…

This study compares two types of surgery to remove lung tumors that have spread from osteosarcoma (a bone cancer). One method uses a single large cut (open surgery), while the other uses several small cuts and a camera (keyhole surgery). The goal is to see which approach helps pa…

This early-phase trial tests a new treatment called Attil12-T cell therapy for people with advanced soft tissue or bone sarcoma that has spread or cannot be removed. The therapy uses a patient's own immune cells, modified to target and attack the tumor. The main goals are to find…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma, Ewing sarcoma, or osteosarcoma) have come back or not responded to treatment. The goal is to find a safe …

This early-phase study tests a new treatment for children whose neuroblastoma or osteosarcoma has come back or not responded to standard therapy. The treatment uses the patient's own T-cells, which are modified in a lab to better recognize and attack cancer cells. The main goals …

This study tests a combination of two drugs, apatinib and liposomal irinotecan, in people with advanced osteosarcoma (bone cancer) that has spread or come back after standard treatments. The goal is to find the safest and most effective dose and see if the combo can shrink tumors…

This study tests whether adding four drugs (gefitinib, trametinib, disulfiram, and sunitinib) to standard chemotherapy helps people with osteosarcoma that has spread. About 45 participants with newly diagnosed or advanced disease will be enrolled. Researchers will check if the co…

This early-stage study tests whether giving children with high-risk solid tumors a special type of immune cell (called TAA-T) is safe. The cells are designed to recognize and attack proteins found on tumor cells. Up to 36 children whose cancer has not responded to standard treatm…

This expanded access program provides DNG64-CAR-V, a gene therapy, to patients with advanced pancreatic cancer, sarcoma, or breast cancer who have exhausted standard treatments. The therapy is given intravenously or directly into tumors, alone or with other cancer drugs. Early st…

This study tests whether the drug regorafenib can help prevent bone sarcomas from coming back after initial treatment. About 168 people aged 12 and older with various bone sarcomas will be randomly assigned to take regorafenib for up to 12 months or to receive standard monitoring…

This phase 2 trial tests whether the drug regorafenib can help keep high-grade bone sarcomas from growing in patients who still have some disease after standard treatment. About 36 people aged 12 and older will take regorafenib daily for up to 12 months. The main goal is to see h…

This study tests a new drug called PEEL-224 combined with two standard chemotherapy drugs (vincristine and temozolomide) in adolescents and young adults whose sarcomas have returned or not responded to treatment. The trial has two phases: first, finding the safest dose, then chec…

This early-stage study tests a new treatment for children and young adults up to age 21 with sarcomas that have come back or not responded to standard therapy. The treatment combines a special type of immune cell (B7-H3-CAR T cells) with targeted radiation and chemotherapy to see…

This study tests a new treatment called afamitresgene autoleucel in children and young adults aged 2 to 21 with advanced cancers that have a specific marker (MAGE-A4). The treatment uses the patient's own immune cells, modified to attack the cancer. The main goals are to check sa…

This study tests whether adding specially trained donor immune cells (NK cells) to standard chemotherapy can help children and young adults with sarcomas that have returned or not responded to treatment. About 50 participants aged 2 to 40 will receive up to 8 cycles of chemo plus…

This study tests whether a new type of immune cell therapy (HER2-CAR T cells) combined with drugs that boost the immune system (pembrolizumab or nivolumab) is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before the cell infusion to help t…

This early-stage trial tests a new drug called GAIA-102 in children whose neuroblastoma or other solid tumors have not responded to standard treatments. The study has four groups, testing GAIA-102 alone or combined with other cancer drugs. The main goal is to check safety and fin…

This early-phase trial tests the safety and best dose of cabozantinib combined with high-dose ifosfamide in 30 children and adults with sarcomas (like Ewing sarcoma or osteosarcoma) that have returned or not responded to standard chemotherapy. The goal is to find a dose that cont…

This early-phase trial tests a new type of stem cell transplant for children with blood cancers or solid tumors that have relapsed or not responded to standard treatment. Doctors use a half-matched donor's stem cells, specially filtered to remove certain immune cells, and give th…

This study tests two drugs, pembrolizumab and cabozantinib, together in people with advanced sarcomas (cancers of the soft tissue or bone) that have not responded to standard treatments. The goal is to see if the combination can stop or shrink tumors for at least 6 months. About …

This early-stage trial is testing a new drug called AOH1996 in 92 adults with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. The drug works by blocking a protein that cancer cells need to grow. The main goals are to fi…

This study tests a special dye called Cytalux that makes cancer cells glow under near-infrared light. Surgeons use it during lung surgery to find and remove hard-to-see tumors in teens (ages 6-17) with bone cancer that has spread to the lungs. The goal is to see if the dye helps …

This study compares whole-body MRI, PET/MR, and PET/CT scans to see which is best at finding tumors in children and young adults with solid tumors, lymphoma, or osteosarcoma. Researchers will check how many tumors each scan detects and measure their metabolic activity. The goal i…

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This study is testing whether a smartwatch can track changes in walking and daily activities in people with bone cancer (osteosarcoma or metastatic bone disease). The goal is to see if the watch can help doctors spot problems early and personalize care. About 60 participants will…

This study is testing whether growing a patient's osteosarcoma cells in the lab (as organoids) can predict which chemotherapy drugs will work best. Researchers will take tissue from routine biopsies or surgeries of 40 people with suspected or confirmed osteosarcoma. The goal is t…

This study follows 300 people who had surgery to remove bone tumors (like osteosarcoma or chondrosarcoma). Researchers want to see how well the bone heals and how much function returns over 3 years. Participants fill out questionnaires about their daily activities. No new drug or…

This pilot study looks at 10 people with a new, high-grade bone cancer (osteosarcoma) in an arm or leg. The goal is to see if removing the tumor with surgery before starting chemotherapy leads to better arm or leg function and quality of life. Participants and their surgeons will…

This study looks at whether using 3D printed models of a patient's bones helps surgeons plan and perform tumor removal more effectively. About 150 people with bone tumors will take part, and half will have their surgery planned with both 3D models and regular scans, while the oth…

This study looks at how well bone cancer patients follow a personalized home exercise program in the first six months after lower leg surgery. Researchers will track daily exercise logs from 50 patients and explore what factors help or hinder adherence. The goal is to learn how t…

This early-phase trial is testing two new antibody fragments that are designed to attach to a sugar molecule found on many solid tumors. The fragments are labeled with a radioactive tracer so they can be seen on PET/CT scans. The study aims to see where these fragments go in the …

This observational study is tracking 150 people whose high-grade osteosarcoma has come back near where it started. Researchers want to find out what factors affect how long people live after this type of relapse. The study will look at past and future cases to gather information …

This study is developing a new way to deliver chemotherapy directly to sarcoma tumors using tiny particles activated by light through an optic fiber. Researchers will test these nanoparticles on cells and tissue samples from 30 patients with bone or soft tissue sarcomas. The goal…